About Us

ACell, Inc. offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix (“ECM”) devices to repair and remodel damaged tissues and organs in a broad range of surgical procedures. ACell’s patented ECM devices are covered by multiple U.S. Food and Drug Administration (“FDA”) clearances and address important unmet clinical needs, providing safe, effective and economic therapeutic outcomes to the surgical community.

These devices, referred to in studies and medical journals as UBM (Urinary Bladder Matrix) and trademarked as MatriStem^®, are derived from specific tissue layers of porcine urinary bladder and comprise a naturally occurring, noncrosslinked, completely resorbable, acellular biomaterial. MatriStem devices contain multiple naturally occurring growth factors, multiple collagen types and feature a basement membrane surface which is ideal for epithelial cell growth in many applications. All MatriStem devices are made at ACell’s FDA registered cGMP manufacturing facility in Lafayette, IN.